Hydrocortisone Alternatives Compared
| Hydrocortisone | Humira (adalimumab) | Entyvio (vedolizumab) |
|
|---|
| Hydrocortisone | Humira (adalimumab) | Entyvio (vedolizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Adrenocortical Insufficiency, Addison's Disease, Asthma - acute, Ulcerative Proctitis, Crohn's Disease - Active, Inflammatory Bowel Disease, Inflammatory Conditions, Shock, Ulcerative... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Related suggestions Ulcerative Colitis
Popular comparisons
|
|||||||||||||||||||||||
| More about Hydrocortisone | More about Humira (adalimumab) | More about Entyvio (vedolizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Hydrocortisone has an average rating of 7.5 out of 10 from a total of 31 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 10% reported a negative effect. |
Humira has an average rating of 6.4 out of 10 from a total of 703 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 30% reported a negative effect. |
Entyvio has an average rating of 6.3 out of 10 from a total of 166 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 28% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Hydrocortisone side effects |
View all Humira side effects |
View all Entyvio side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Hydrocortisone prices |
View all Humira prices |
View all Entyvio prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Alkindi Sprinkle, Cortef, Cortenema, Cortifoam, Khindivi, Solu-Cortef | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | Other vedolizumab brands include: Entyvio Pen | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
12 hours |
480 hours |
600 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 643 drugs are known to interact with Hydrocortisone:
|
A total of 555 drugs are known to interact with Humira:
|
A total of 169 drugs are known to interact with Entyvio:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
December 21, 1951 |
December 31, 2002 |
May 20, 2014 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Omvoh
Omvoh is used to treat moderate to severe ulcerative colitis or Crohn's disease in adults. This ...
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Humira
Humira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Dexamethasone Intensol
Dexamethasone Intensol is used for addison's disease, adrenal insufficiency, adrenocortical ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Kenalog-40
Kenalog-40 is a long-acting corticosteroid injection for intramuscular (into the muscle) or ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.